Pacira BioSciences announced the repayment on March 31, 2023 of $287.5 million in Term Loan B debt, which represented all outstanding principal under the facility, using net proceeds from a new $150 million 5-year Term Loan A Facility and existing cash resources. After the debt repayment, the company expects to finish the first quarter of 2023 with approximately $180 million in cash and investments. The $150 million Term Loan A Facility was placed with high-quality commercial banks. JPMorgan Chase Bank, N.A. acted as Sole Lead Arranger / Bookrunner and Administrative Agent.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PCRX:
- Pacira announces FDA clearance of sNDA for EXPAREL label
- Court upholds decision to dismiss Pacira lawsuit against ASA
- Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
- Pacira announces Yvonne Greenstreet to retire from Board
- Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
